Acotec’s 2023 results were disappointing due to VBP and anti-corruption campaign. Growth of core products declined significantly and the cooperation with Boston Scientific failed to meet expectation.
What is covered in the Full Insight:
Introduction
2023 Financial Performance
Core Products Analysis
Competition and Market Position
Future Prospects and Risks
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.